Ignite Creation Date:
2025-12-25 @ 12:56 AM
Ignite Modification Date:
2026-01-01 @ 3:20 PM
Study NCT ID:
NCT05660967
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-02
First Post:
2022-11-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D016403', 'term': 'Lymphoma, Large B-Cell, Diffuse'}], 'ancestors': [{'id': 'D016393', 'term': 'Lymphoma, B-Cell'}, {'id': 'D008228', 'term': 'Lymphoma, Non-Hodgkin'}, {'id': 'D008223', 'term': 'Lymphoma'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077269', 'term': 'Lenalidomide'}], 'ancestors': [{'id': 'D010797', 'term': 'Phthalimides'}, {'id': 'D010795', 'term': 'Phthalic Acids'}, {'id': 'D000146', 'term': 'Acids, Carbocyclic'}, {'id': 'D002264', 'term': 'Carboxylic Acids'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D010881', 'term': 'Piperidones'}, {'id': 'D010880', 'term': 'Piperidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D054833', 'term': 'Isoindoles'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 111}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2023-03-06', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'nctId': 'NCT05733650', 'statusForNctId': 'APPROVED_FOR_MARKETING', 'hasExpandedAccess': True}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2027-07-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-01', 'studyFirstSubmitDate': '2022-11-29', 'studyFirstSubmitQcDate': '2022-12-14', 'lastUpdatePostDateStruct': {'date': '2025-12-02', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2022-12-21', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-01-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Complete Response (CR) rate', 'timeFrame': 'From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years', 'description': 'Percentage of participants achieving CR. Assessed by the Investigator per Lugano criteria'}], 'secondaryOutcomes': [{'measure': 'Duration of response (DOR)', 'timeFrame': 'From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years', 'description': 'Defined as the time between date of first response to the date of first documented tumor progression or death (due to any cause) whichever occurs first'}, {'measure': 'Duration of complete response (DOCR)', 'timeFrame': 'From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years', 'description': 'Defined as the time between the date of first CR to the date of the first documented tumor progression or death due to any cause, whichever comes first'}, {'measure': 'Time to response (TTR)', 'timeFrame': 'From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 1 year', 'description': 'Defined as the time from first dose to first documentation of objective tumor response (CR or PR)'}, {'measure': 'Overall Response Rate (ORR)', 'timeFrame': 'From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years', 'description': 'Defined as the percentage of patients who achieve best overall response of complete response (CR) or partial response (PR) determined by Lugano criteria'}, {'measure': 'Progression-free survival (PFS)', 'timeFrame': 'From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years', 'description': 'Defined as the time from first dose to date of PD or death (due to any cause) whichever occurs first'}, {'measure': 'Time to next anti-lymphoma therapy (TTNT)', 'timeFrame': 'From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years', 'description': 'Defined as the time from first dose to administration of subsequent anti-lymphoma therapy'}, {'measure': 'Rate of minimal residual disease (MRD) negativity', 'timeFrame': 'From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years', 'description': 'Percentage of participants with at least 1 post-screening MRD negative result'}, {'measure': 'Overall survival (OS)', 'timeFrame': 'From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 3 years', 'description': 'Defined at the timeframe from first dose to death'}, {'measure': 'Incidence and severity of adverse events (AEs)', 'timeFrame': 'From screening until end of the safety follow-up period (60 days after last dose)', 'description': 'An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment'}, {'measure': 'Incidence of clinically significant shifts in laboratory parameters', 'timeFrame': 'From screening until end of the safety follow-up period (60 days after last dose)', 'description': 'Clinical laboratory parameters assessed: hematology, chemistry, coagulation, tumor lysis, cardiac enzymes, immunoglobulins, and urinalyses'}, {'measure': 'Incidence of anti-drug antibodies (ADAs) to epcoritamab in plasma', 'timeFrame': 'From first dose until treatment discontinuation (assessed up to 12 months)', 'description': 'To evaluate immunogenicity'}, {'measure': 'Evaluate patient-reported outcomes (PROs) related to lymphoma symptoms', 'timeFrame': 'From cycle 1, day 1 until 90 days after last dose (each cycle is 28 days)', 'description': 'Changes in lymphoma symptoms as measured by the Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym). Scale from 0-168 obtained by summing individual subscale scores. Higher scores for the scales indicate better quality of life'}, {'measure': 'Assess pharmacokinetics (PK) of epcoritamab', 'timeFrame': 'From first dose and at multiple time points until treatment discontinuation (assessed up to 12 months)', 'description': 'Total body clearance of drug from the plasma (CL)'}, {'measure': 'Assess pharmacokinetics (PK) of epcoritamab', 'timeFrame': 'From first dose and at multiple time points until treatment discontinuation (assessed up to 12 months)', 'description': 'Maximum observed concentration (Cmax)'}, {'measure': 'Assess pharmacokinetics (PK) of epcoritamab', 'timeFrame': 'From first dose and at multiple time points until treatment discontinuation (assessed up to 12 months)', 'description': 'Time to reach Cmax (Tmax)'}, {'measure': 'Assess pharmacokinetics (PK) of epcoritamab', 'timeFrame': 'From first dose and at multiple time points until treatment discontinuation (assessed up to 12 months)', 'description': 'Terminal Elimination Half-Life (t 1/2)'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Double-hit lymphoma', 'Triple-hit lymphoma', 'Follicular grade 3B', 'T-cell/histiocyte rich LBCL', 'DuoBody®', 'Anti-CD3', 'Anti-CD20', 'Subcutaneous', 'Bispecific antibody', 'EPCORE'], 'conditions': ['Diffuse Large B-Cell Lymphoma']}, 'descriptionModule': {'briefSummary': 'The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. Epcoritamab (also known as EPKINLY™, GEN3013 and DuoBody®-CD3xCD20) is an antibody that has already been tested in several clinical studies. All patients will receive active treatment. There is an equal chance of receiving epcoritamab or epcoritamab plus lenalidomide.', 'detailedDescription': 'This is an open-label, multicenter, global phase-2 trial evaluating the efficacy and safety of epcoritamab monotherapy and epcoritamab plus lenalidomide in elderly patients who are deemed anthracycline ineligible.\n\nThe trial is designed in two stages:\n\n* Stage 1 which includes a safety run-in phase in each arm\n* Stage 2, an expansion of the selected treatment from Stage 1'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['OLDER_ADULT'], 'minimumAge': '75 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Must have newly diagnosed CD20+ large cell lymphoma.\n* Is ineligible for anthracycline-based therapy/cytotoxic chemotherapy due to:\n\n * Being age ≥80 years; AND/OR\n * Being age ≥75 years and having important comorbid condition(s), which are likely to have a negative impact on tolerability of anthracycline-based therapy/cytotoxic chemotherapy.\n* Have Immune Effector Cell-Associated Encephalopathy (ICE) score of at least 8 out of 10.\n* Have Ann Arbor Stage II-IV disease.\n* Have ECOG PS of 0, 1, or 2; (ECOG PS of 3 may be considered if impairment is attributed to current lymphoma/DLBCL and if pre-phase treatment during the screening phase results in an improvement of ECOG PS to ≤2 prior to enrollment).\n* Have measurable disease as per Lugano criteria.\n* Have acceptable organ function based on baseline bloodwork.\n* Must have fresh (preferred) or archival biopsy material at screening.\n\nExclusion Criteria:\n\n* Has known active, clinically significant bacterial, viral, fungal, mycobacterial, parasitic, or other infection at trial enrollment, including COVID-19 infection.\n* Has severe cardiovascular disease (other than those eligibility criteria that preclude the subject from receiving anthracycline-based therapy/cytotoxic chemotherapy),\n* Has been exposed to/received any of the following prior therapies, treatments, or procedures within the specified timeframes:\n\n * Major surgery within 4 weeks prior to the first dose of epcoritamab;\n * Non-investigational antineoplastic agents (except anti-CD20 monoclonal antibodies) or any investigational drug within 4 weeks or 5 half-lives, whichever is shorter, prior to the first dose of epcoritamab;\n * Autologous hematopoietic stem cell transplantation (HSCT), CAR-T, allogeneic stem cell transplantation, or solid organ transplantation;\n * Live, attenuated vaccines within 30 days prior to initiation of epcoritamab;\n * Investigational vaccines within 28 days before the planned first dose of epcoritamab (ie, experimental and/or non-authorized SARS-CoV-2 vaccinations and therapies are not allowed);\n * Invasive investigational medical device use within 28 days before the planned first dose of epcoritamab.\n* Has primary central nervous system (CNS) tumor or known CNS involvement or intracranial involvement as confirmed by mandatory brain magnetic resonance imaging/computed tomography (MRI/CT) scan at screening and, if clinically indicated, by lumbar puncture.\n* Has a seizure disorder requiring anti-epileptic therapy or experienced a seizure within 6 months of signing an informed consent form.\n* Has known past or current malignancy other than inclusion diagnosis, with exceptions as stated in protocol.\n* Has known or suspected allergies, hypersensitivity, or intolerance to either of the trial treatments or has known or suspected contraindication to the use of all locally available anti-cytokine therapies per local guidelines for management of cytokine release syndrome (CRS).\n* Has active hepatitis B virus (HBV) (DNA polymerase chain reaction \\[PCR\\]-positive) or hepatitis C virus (HCV) (RNA PCR-positive) infection, current alcohol abuse, or cirrhosis.\n* Has active cytomegalovirus (CMV) infection (DNA PCR-positive) requiring treatment.\n* Has suspected active or inadequately treated latent tuberculosis.\n* Has a known history of seropositivity for HIV. Note: HIV testing is required at screening only if required per local health authorities or institutional standards.\n\nNote: Other protocol defined inclusion/exclusion criteria may apply.'}, 'identificationModule': {'nctId': 'NCT05660967', 'acronym': 'EPCORE DLBCL-3', 'briefTitle': 'Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma', 'organization': {'class': 'INDUSTRY', 'fullName': 'Genmab'}, 'officialTitle': 'Efficacy and Safety of Epcoritamab Monotherapy and in Combination With Lenalidomide as First-line Therapy for Anthracycline-ineligible Diffuse Large B-Cell Lymphoma Patients, an Open-label, Randomized, Multicenter, Global Phase 2 Trial', 'orgStudyIdInfo': {'id': 'GCT3013-06'}, 'secondaryIdInfos': [{'id': '2021-005744-29', 'type': 'EUDRACT_NUMBER'}, {'id': 'jRCT2021230015', 'type': 'REGISTRY', 'domain': 'Japan Registry for Clinical Trials (jRCT)'}, {'id': '1006219', 'type': 'OTHER', 'domain': 'IRAS ID; UK Research Summaries Database'}, {'id': '2023-504832-16-00', 'type': 'CTIS'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Epcoritamab monotherapy', 'interventionNames': ['Biological: Epcoritamab']}, {'type': 'EXPERIMENTAL', 'label': 'Epcoritamab in combination with lenalidomide', 'interventionNames': ['Biological: Epcoritamab', 'Drug: Lenalidomide']}], 'interventions': [{'name': 'Epcoritamab', 'type': 'BIOLOGICAL', 'otherNames': ['GEN3013', 'DuoBody®-CD3×CD20', 'EPKINLY™'], 'description': 'Epcoritamab will be administered by subcutaneous (SC) injections in 28-day cycles for up to 12 cycles.', 'armGroupLabels': ['Epcoritamab in combination with lenalidomide', 'Epcoritamab monotherapy']}, {'name': 'Lenalidomide', 'type': 'DRUG', 'otherNames': ['Revlimid®'], 'description': 'Lenalidomide will be administered orally (capsules; starting dose of 10 or 20 mg) once daily on Day 1 to Day 21 of each 28-day cycle for up to 12 cycles.', 'armGroupLabels': ['Epcoritamab in combination with lenalidomide']}]}, 'contactsLocationsModule': {'locations': [{'zip': '53188', 'city': 'Waukesha', 'state': 'Wisconsin', 'country': 'United States', 'facility': 'UW Cancer Center at ProHealth Care', 'geoPoint': {'lat': 43.01168, 'lon': -88.23148}}, {'city': 'Linz', 'country': 'Austria', 'facility': 'Kepler Universitätsklinikum', 'geoPoint': {'lat': 48.30639, 'lon': 14.28611}}, {'city': 'Salzburg', 'country': 'Austria', 'facility': 'LKH - Universitätsklinikum der PMU Salzburg', 'geoPoint': {'lat': 47.79941, 'lon': 13.04399}}, {'city': 'Wels', 'country': 'Austria', 'facility': 'Klinikum Wels-Grieskirchen GmbH', 'geoPoint': {'lat': 48.16667, 'lon': 14.03333}}, {'city': 'Anderlecht', 'country': 'Belgium', 'facility': 'Institut Jules Bordet', 'geoPoint': {'lat': 50.83619, 'lon': 4.31454}}, {'city': 'Antwerp', 'country': 'Belgium', 'facility': 'ZNA', 'geoPoint': {'lat': 51.22047, 'lon': 4.40026}}, {'city': 'Jette', 'country': 'Belgium', 'facility': 'UZ Brussels', 'geoPoint': {'lat': 50.87309, 'lon': 4.33419}}, {'city': 'Leuven', 'country': 'Belgium', 'facility': 'UZ Leuven', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'city': 'Roeselare', 'country': 'Belgium', 'facility': 'AZ Delta', 'geoPoint': {'lat': 50.94653, 'lon': 3.12269}}, {'city': 'Temse', 'country': 'Belgium', 'facility': 'Vitaz', 'geoPoint': {'lat': 51.12794, 'lon': 4.21372}}, {'city': 'Turnhout', 'country': 'Belgium', 'facility': 'AZ Turnhout - Campus Sint-Elisabeth', 'geoPoint': {'lat': 51.32254, 'lon': 4.94471}}, {'city': 'Hradec Králové', 'country': 'Czechia', 'facility': 'Fakultni nemocnice Hradec Kralove', 'geoPoint': {'lat': 50.20923, 'lon': 15.83277}}, {'city': 'Prague', 'country': 'Czechia', 'facility': 'Fakultni nemocnice v Motole', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'city': 'Prague', 'country': 'Czechia', 'facility': 'Vseobecna fakultni nemocnice v Praze', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'city': 'Angers', 'country': 'France', 'facility': 'CHU Angers - Hôpital Hôtel Dieu', 'geoPoint': {'lat': 47.47156, 'lon': -0.55202}}, {'city': 'Créteil', 'country': 'France', 'facility': 'Hôpital Henri Mondor', 'geoPoint': {'lat': 48.79266, 'lon': 2.46569}}, {'city': 'Lille', 'country': 'France', 'facility': 'Hopital Claude Huriez - CHRU Lille', 'geoPoint': {'lat': 50.63391, 'lon': 3.05512}}, {'city': 'Marseille', 'country': 'France', 'facility': 'Hopital de la Conception - APHM', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'city': 'Nantes', 'country': 'France', 'facility': 'CHU de Nantes - Hotel Dieu', 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'city': 'Paris', 'country': 'France', 'facility': 'Hôpital Saint-Antoine', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'city': 'Paris', 'country': 'France', 'facility': 'Hôpital Saint-Louis', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'city': 'Pessac', 'country': 'France', 'facility': 'CHU de Bordeaux - Hôpital Haut-Lévêque', 'geoPoint': {'lat': 44.80565, 'lon': -0.6324}}, {'city': 'Salouël', 'country': 'France', 'facility': 'CHU Amiens - Hopital Sud', 'geoPoint': {'lat': 49.86988, 'lon': 2.2434}}, {'city': 'Tours', 'country': 'France', 'facility': 'CHU Tours - Hôpital Bretonneau', 'geoPoint': {'lat': 47.39484, 'lon': 0.70398}}, {'city': 'Freiburg im Breisgau', 'state': 'Baden-Wurttemberg', 'country': 'Germany', 'facility': 'Universitaetsklinikum Freiburg', 'geoPoint': {'lat': 47.9959, 'lon': 7.85222}}, {'city': 'Aachen', 'country': 'Germany', 'facility': 'Universitaetsklinikum Aachen AOeR', 'geoPoint': {'lat': 50.77664, 'lon': 6.08342}}, {'city': 'Berlin', 'country': 'Germany', 'facility': 'Vivantes Klinikum Neukoelln', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'city': 'Würzburg', 'country': 'Germany', 'facility': 'Universitaetsklinikum Wuerzburg', 'geoPoint': {'lat': 49.79391, 'lon': 9.95121}}, {'city': 'Ancona', 'country': 'Italy', 'facility': 'Clinica di Ematologia AOU Ospedali Riuniti di Ancona', 'geoPoint': {'lat': 43.60717, 'lon': 13.5103}}, {'city': 'Aviano', 'country': 'Italy', 'facility': 'IRCCS Centro di Riferimento Oncologico', 'geoPoint': {'lat': 46.07056, 'lon': 12.59472}}, {'city': 'Bologna', 'country': 'Italy', 'facility': "Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS", 'geoPoint': {'lat': 44.49381, 'lon': 11.33875}}, {'city': 'Brescia', 'country': 'Italy', 'facility': 'Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)', 'geoPoint': {'lat': 45.53558, 'lon': 10.21472}}, {'city': 'Candiolo', 'country': 'Italy', 'facility': "Fondazione del Piemonte per l'Oncologia IRCC Candiolo", 'geoPoint': {'lat': 44.95858, 'lon': 7.59812}}, {'city': 'Meldola', 'country': 'Italy', 'facility': 'IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" - IRST', 'geoPoint': {'lat': 44.12775, 'lon': 12.0626}}, {'city': 'Milan', 'country': 'Italy', 'facility': 'IEO Istituto Europeo di Oncologia Parent', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'city': 'Milan', 'country': 'Italy', 'facility': 'Ospedale San Raffaele', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'city': 'Palermo', 'country': 'Italy', 'facility': 'Azienda Ospedaliera Vincenzo Cervello', 'geoPoint': {'lat': 38.1166, 'lon': 13.3636}}, {'city': 'Piacenza', 'country': 'Italy', 'facility': 'AUSL Piacenza Ospedale Guglielmo da Saliceto', 'geoPoint': {'lat': 45.05242, 'lon': 9.69342}}, {'city': 'Trieste', 'country': 'Italy', 'facility': 'Azienda sanitaria integrata università di Trieste', 'geoPoint': {'lat': 45.64953, 'lon': 13.77678}}, {'city': 'Fukuoka', 'country': 'Japan', 'facility': 'Kyushu University Hospital', 'geoPoint': {'lat': 33.6, 'lon': 130.41667}}, {'city': 'Kagoshima', 'country': 'Japan', 'facility': 'Kagoshima University Hospital', 'geoPoint': {'lat': 31.56667, 'lon': 130.55}}, {'city': 'Kanazawa', 'country': 'Japan', 'facility': 'Kanazawa University Hospital', 'geoPoint': {'lat': 36.6, 'lon': 136.61667}}, {'city': 'Kashiwa', 'country': 'Japan', 'facility': 'National Cancer Center Hospital East', 'geoPoint': {'lat': 35.86224, 'lon': 139.97732}}, {'city': 'Kōtoku', 'country': 'Japan', 'facility': 'Cancer Institute Hospital of JFCR', 'geoPoint': {'lat': 42.50417, 'lon': 143.14297}}, {'city': 'Matsuyama', 'country': 'Japan', 'facility': 'Matsuyama Red Cross Hospital', 'geoPoint': {'lat': 33.83916, 'lon': 132.76574}}, {'city': 'Nagoya', 'country': 'Japan', 'facility': 'NHO Nagoya Medical Center', 'geoPoint': {'lat': 35.18147, 'lon': 136.90641}}, {'city': 'Ōsaka-sayama', 'country': 'Japan', 'facility': 'Kindai University Hospital', 'geoPoint': {'lat': 34.49524, 'lon': 135.55069}}, {'city': 'Yamagata', 'country': 'Japan', 'facility': 'Yamagata University Hospital', 'geoPoint': {'lat': 38.23333, 'lon': 140.36667}}, {'city': 'Biała Podlaska', 'country': 'Poland', 'facility': 'Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej', 'geoPoint': {'lat': 52.03238, 'lon': 23.11652}}, {'city': 'Krakow', 'country': 'Poland', 'facility': 'Pratia MCM Krakow', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'city': 'Skorzewo', 'country': 'Poland', 'facility': 'Centrum Medyczne Pratia Poznan', 'geoPoint': {'lat': 54.16909, 'lon': 17.97006}}, {'city': 'Torun', 'country': 'Poland', 'facility': 'MICS Centrum Medyczne Torun', 'geoPoint': {'lat': 53.01375, 'lon': 18.59814}}, {'city': 'Daegu', 'country': 'South Korea', 'facility': 'Keimyung University Dongsan Hospital', 'geoPoint': {'lat': 35.87028, 'lon': 128.59111}}, {'city': 'Goyang-si', 'country': 'South Korea', 'facility': 'National Cancer Center', 'geoPoint': {'lat': 37.65639, 'lon': 126.835}}, {'city': 'Jeonju', 'country': 'South Korea', 'facility': 'Jeonbuk National University Hospital', 'geoPoint': {'lat': 35.82194, 'lon': 127.14889}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Asan Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Samsung Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Seoul', 'country': 'South Korea', 'facility': 'Seoul National University Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'city': 'Badalona', 'country': 'Spain', 'facility': 'ICO Badalona - Hospital Universitari Germans Trias i Pujol', 'geoPoint': {'lat': 41.45004, 'lon': 2.24741}}, {'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital Clinic de Barcelona', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'city': 'Barcelona', 'country': 'Spain', 'facility': "ICO l'Hospitalet - Hospital Duran i Reynals", 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'city': 'Cáceres', 'country': 'Spain', 'facility': 'Hospital San Pedro de Alcantara', 'geoPoint': {'lat': 39.47649, 'lon': -6.37224}}, {'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital General Universitario Gregorio Marañon', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario 12 de Octubre', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario Fundacion Jimenez Diaz', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario Ramon y Cajal', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Seville', 'country': 'Spain', 'facility': 'Hospital Universitario Nuestra Señora de Valme', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'city': 'Seville', 'country': 'Spain', 'facility': 'Hospital Universitario Puerta del Mar', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'city': 'Seville', 'country': 'Spain', 'facility': 'Hospital Universitario Virgen Macarena', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'city': 'London', 'country': 'United Kingdom', 'facility': 'Royal Marsden Hospital - Fulham', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'city': 'Plymouth', 'country': 'United Kingdom', 'facility': 'Derriford Hospital', 'geoPoint': {'lat': 50.37153, 'lon': -4.14305}}, {'city': 'Southampton', 'country': 'United Kingdom', 'facility': 'Southampton General Hospital', 'geoPoint': {'lat': 50.90395, 'lon': -1.40428}}, {'city': 'Sutton', 'country': 'United Kingdom', 'facility': 'Royal Marsden Hospital', 'geoPoint': {'lat': 51.35, 'lon': -0.2}}, {'city': 'Truro', 'country': 'United Kingdom', 'facility': 'Royal Cornwall Hospital NHS Trust', 'geoPoint': {'lat': 50.26526, 'lon': -5.05436}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Genmab', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'AbbVie', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}